过氧化物酶体增殖物激活受体γ在炎症相关疾病中作用的研究进展

doi:10.3969/j.issn.1673-8640.2017.02.019

检验医学 ›› 2017, Vol. 32 ›› Issue (2): 153-157.DOI: 10.3969/j.issn.1673-8640.2017.02.019

过氧化物酶体增殖物激活受体γ在炎症相关疾病中作用的研究进展

任润健, 赵虎, 毕波

复旦大学附属华东医院检验科,上海 200040

收稿日期:2016-05-04 出版日期:2017-03-30 发布日期:2017-03-30
作者简介:null
作者简介：任润健,女,1992年生,学士,主要从事皮肤衰老机制研究。

通信作者：毕波,联系电话：021-62483180。
基金资助:
国家自然科学基金项目（81301642）

Research progress of peroxisome proliferator-activated receptor gamma in inflammatory-related diseases

REN Runjian, ZHAO Hu, BI Bo

Department of Clinical Laboratory,Huadong Hospital,Fudan University,Shanghai 200040,China

Received:2016-05-04 Online:2017-03-30 Published:2017-03-30

摘要/Abstract

摘要：

过氧化物酶体增殖物激活受体γ（PPARγ）是一种配体依赖性转录因子,属Ⅱ型核受体超家族成员。近年来的研究表明,配体激活的PPARγ能够调控大量基因表达,参与抗肥胖、抗动脉粥样硬化、抗糖尿病、抗肿瘤、抗皮肤炎症性疾病等机体众多的生理和病理过程,而这些疾病与炎症息息相关。因此,文章主要就PPARγ在炎症以及炎症相关疾病中的研究进展作一综述。

关键词: 过氧化物酶体增殖物激活受体γ, 炎症, 配体

Abstract:

Peroxisome proliferator-activated receptor gamma（PPARγ）is a member of type Ⅱ nuclear receptor superfamily,as a ligand-dependent transcription factor. In recent years,studies have shown that activated PPARγ is capable of modulating the expression of numerous genes and is involved in many physiological and pathological processes,including anti-obesity,anti-atherosclerosis,anti-diabetes mellitus,anti-cancer and anti-inflammatory skin diseases. These diseases are closely related to inflammation. In this review,the research progress of PPARγ in inflammation and inflammatory-related diseases will be summarized.

Key words: Peroxisome proliferator-activated receptor gamma, Inflammation, Ligand

中图分类号:

R446.62

任润健, 赵虎, 毕波. 过氧化物酶体增殖物激活受体γ在炎症相关疾病中作用的研究进展[J]. 检验医学, 2017, 32(2): 153-157.

REN Runjian, ZHAO Hu, BI Bo. Research progress of peroxisome proliferator-activated receptor gamma in inflammatory-related diseases[J]. Laboratory Medicine, 2017, 32(2): 153-157.

参考文献 31

[1]	.JANANI C,RANJITHA KUMARI B D. PPAR gamma gene-A review[J]. Diabetes Metab Syndr,2015,9(1):46-50.
[2]	.SUGAWARA A,URUNO A,KUDO M,et al.PPARγ agonist beyond glucose lowering effect[J]. Korean J Intern Med,2011,26(1):19-24.
[3]	.TAKADA I, MAKISHIMA M.PPARγ ligands and their therapeutic applications:a patent review (2008-2014)[J]. Expert Opin Ther Pat,2015,25(2):175-191.
[4]	.ZOETE V,GROSDIDIER A,MICHIELIN O.Peroxisome proliferator-activated receptor structures:ligand specificity,molecular switch and interactions with regulators[J]. Biochim Biophys Acta,2007,1771(8):915-925.
[5]	.HALLENBORG P,PETERSEN R K,KOUSKOUMVEKAKI I,et al.The elusive endogenous adipogenic PPARγ agonists:lining up the suspects[J]. Prog Lipid Res,2016,61:149-162.
[6]	.AHMADIAN M,SUH J M,HAH N,et al.PPARγ signaling and metabolism:the good,the bad and the future[J]. Nat Med,2013,19(5):557-566.
[7]	.KIM J H,SONG J,PARK K W.The multifaceted factor peroxisome proliferator-activated receptor γ(PPARγ) in metabolism,immunity,and cancer[J]. Arch Pharm Res,2015,38(3):302-312.
[8]	.BRIGANTI S,FLORI E,BELLEI B,et al.Modulation of PPARγ provides new insights in a stress induced premature senescence model[J]. PLoS One,2014,9(8):e104045.
[9]	.ULRICH-LAI Y M,RYAN K K. PPARγ and stress:implications for aging[J]. Exp Gerontol,2013,48(7):671-676.
[10]	.CROASDELL A,DUFFNEY P F,KIM N,et al.PPARγ and the innate immune system mediate the resolution of inflammation[J]. PPAR Res,2015,2015:549691.
[11]	.KIM J K,MUN S,KIM M S,et al.5,7-Dimethoxyflavone,an activator of PPARα/γ,inhibits UVB-induced MMP expression in human skin fibroblast cells[J]. Exp Dermatol,2012,21(3):211-216.
[12]	.BRIGANTI S,FLORI E,MASTROFRANCESCO A,et al.Azelaic acid reduced senescence-like phenotype in photo-irradiated human dermal fibroblasts:possible implication of PPARγ[J]. Exp Dermatol,2013,22(1):41-47.
[13]	.LEE Y H,LEE N H,BHATTARAI G,et al.PPARgamma inhibits inflammatory reaction in oxidative stress induced human diploid fibloblast[J]. Cell Biochem Funct,2010,28(6):490-496.
[14]	.FERRONI P,DELLA-MORTE D,PILEGGI A,et al.Pleiotropic effects of PPARγ agonist on hemostatic activation in type 2 diabetes mellitus[J]. Curr Vasc Pharmacol,2013,11(3):338-351.
[15]	.DONG C,ZHOU H,SHEN C,et al.Role of peroxisome proliferator-activated receptors gene polymorphisms in type 2 diabetes and metabolic syndrome[J]. World J Diabetes,2015,6(4):654-661.
[16]	.CARIOU B,CHARBONNEL B,STAELS B.Thiazolidinediones and PPARγ agonists:time for a reassessment[J]. Trends Endocrinol Metab,2012,23(5):205-215.
[17]	.MONTAGNER A,RANDO G,DEGUEURCE G,et al.New insights into the role of PPARs[J]. Prostaglandins Leukot Essent Fatty Acids,2011,85(5):235-243.
[18]	.CELINSKI K,DWORZANSKI T,FORNAL R,et al.Comparison of the anti-inflammatory and therapeutic actions of PPAR-gamma agonists rosiglitazone and troglitazone in experimental colitis[J]. J Physiol Pharmacol,2012,63(6):631-640.
[19]	.BOCHNER B S.Novel therapies for eosinophilic disorders[J]. Immunol Allergy Clin North Am,2015,35(3):577-598.
[20]	.POL C J,LIEU M,DROSATOS K.PPARs:protectors or opponents of myocardial function?[J]. PPAR Res,2015,2015:835985.
[21]	.LIU J,WANG L N. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack[J]. Cochrane Database Syst Rev,2015,10:CD10693.
[22]	.LEE W S,KIM J.Peroxisome proliferator-activated receptors and the heart:lessons from the past and future directions[J]. PPAR Res,2015,2015:271983.
[23]	.CAMPOS A C,FOGACA M V,SONEGO A B,et al.Cannabidiol,neuroprotection and neuropsychiatric disorders[J]. Pharmacol Res,2016,112:119-127.
[24]	.QUINTANILLA R A,UTRERAS E,CABEZAS-OPAZO FA.Role of PPARγ in the differentiation and function of neurons[J]. PPAR Res,2014,2014:768594.
[25]	.BERGER J,MOLLER D E.The mechanisms of action of PPARs[J]. Annu Rev Med,2002,53:409-435.
[26]	.李颀,王岩,邱一凡,等. ALOX12基因多态性与糖尿病和糖尿病肾病的相关性研究[J]. 检验医学,2014,29(3):219-225.
[27]	.周贤会,郭开军. 胰岛素联合罗格列酮治疗2型糖尿病患者血清IL-6和脂联素水平的变化[J]. 检验医学,2008,23(1):14-17.
[28]	.REN P,ZHANG Y,HUANG Y,et al.Functions of peroxisome proliferator-activated receptor gamma (PPARγ) in gynecologic disorders[J]. Clin Med Insights Oncol,2015,9:43-49.
[29]	.MARTIN H.Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components[J]. Mutat Res,2009,669(1-2):1-7.
[30]	.LEHRKE M,LAZAR M A.The many faces of PPARgamma[J]. Cell,2005,123(6):993-999.
[31]	.BERNARDO A,MINGHETTI L.PPAR-gamma agonists as regulators of microglial activation and brain inflammation[J]. Curr Pharm Des,2006,12(1):93-109.

过氧化物酶体增殖物激活受体γ在炎症相关疾病中作用的研究进展

Research progress of peroxisome proliferator-activated receptor gamma in inflammatory-related diseases

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 31

相关文章 15

编辑推荐

Metrics

[1]	彭伟, 李运改, 许静, 刘华, 杨翠霞, 沈云岳. 血清炎症因子联合PSA、f-PSA可辅助诊断前列腺癌[J]. 检验医学, 2023, 38(9): 849-854.
[2]	刘亚楠, 夏敏, 胡韶华, 郑月, 张泓. 淋巴细胞亚群、炎症因子和氨基末端B型钠尿肽原联合检测诊断川崎病[J]. 检验医学, 2023, 38(6): 532-537.
[3]	刘庆阳, 袁建明, 夏进军, 姜风英, 王秋波, 王晓明. 基于GEO数据库和临床样本验证CXCL9作为类风湿关节炎生物标志物的研究[J]. 检验医学, 2023, 38(12): 1121-1129.
[4]	杨茜岚, 汪金玉, 刘舒予, 占伊扬, 刘菁, 贾坚. 南京市鼓楼社区老年人群高脂血症与内皮细胞微粒的相关性[J]. 检验医学, 2023, 38(12): 1167-1172.
[5]	朱倩, 褚丽芳, 马彩云, 姚洁. 血清miR-140-5p、PGC-1α mRNA表达与急性缺血性脑卒中患者血管性认知障碍的相关性[J]. 检验医学, 2023, 38(11): 1069-1074.
[6]	徐镠粤, 廖庆华, 彭柯皓, 余美玲, 陈燕梅, 卓文基, 赖晓宇. 核酸适配体荧光探针法和液基夹层杯法检测结核分枝杆菌临床应用价值比较[J]. 检验医学, 2023, 38(10): 915-918.
[7]	滑世轩, 代淑阳, 李冰洁, 岑东, 许泼实. 血脂正常冠心病患者炎症因子水平与病情严重程度的关系[J]. 检验医学, 2023, 38(1): 66-68.
[8]	刘洋, 耿坤静, 栗红江, 石昊曦, 陈思思. 25（OH）D₃与肝脏炎症分期和抗病毒疗效的相关性分析[J]. 检验医学, 2022, 37(7): 628-631.
[9]	杜宇平, 陈阳. sCD147、sCD40L、miR-21与ACI患者颈动脉粥样斑块类型及预后的关系[J]. 检验医学, 2022, 37(7): 636-640.
[10]	赵莺, 徐锦. 粪便钙卫蛋白在儿童炎症性肠病中的临床意义[J]. 检验医学, 2022, 37(5): 429-432.
[11]	冯雪晴, 居漪, 李卿, 金中淦. 电化学适配体传感器检测生物标志物研究进展[J]. 检验医学, 2022, 37(5): 477-482.
[12]	孙小丹, 许静, 刘鷖雯, 何怡青, 杜艳, 张国良, 高锋, 杨翠霞. 选择性ER调节剂对骨肉瘤细胞增殖及CCL2表达的抑制作用研究[J]. 检验医学, 2022, 37(4): 319-324.
[13]	宋云霄, 童巍, 张海晨, 张银网, 卞晓波, 张琳琳, 袁文华, 赵智赟, 葛雯, 姚天悦. 系统性炎症指标与老年骨质疏松症患者骨折发生的相关性[J]. 检验医学, 2022, 37(3): 235-239.
[14]	喻蕾, 郝新斌, 葛秋颖. 急性脑梗死患者CXCL12、PTX-3、FⅦa/FⅦAg比值与定量脑电图指标的相关性[J]. 检验医学, 2022, 37(2): 194-195.
[15]	赵晓敏, 江晓宇, 单凯莉, 单铁英, 刘秀珍. 缺铁性贫血患儿Flt-3L、TF、25（OH）D检测的临床意义[J]. 检验医学, 2022, 37(11): 1039-1043.